Combination of MP1 with temsirolimus further significantly suppressed tumor growth by approximately 40% (compared to temsirolimus) and 60% (compared to MP1), suggesting the antitumor combination potential of MP1 with temsirolimus against MYC-driven MB in vivo. Here, MYC is linked to neoplasm.